U.S. markets closed
  • S&P Futures

    4,441.75
    +3.75 (+0.08%)
     
  • Dow Futures

    34,659.00
    +15.00 (+0.04%)
     
  • Nasdaq Futures

    15,307.00
    +3.50 (+0.02%)
     
  • Russell 2000 Futures

    2,255.40
    +0.20 (+0.01%)
     
  • Crude Oil

    73.42
    +0.12 (+0.16%)
     
  • Gold

    1,749.30
    -0.50 (-0.03%)
     
  • Silver

    22.63
    -0.05 (-0.22%)
     
  • EUR/USD

    1.1743
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • Vix

    18.63
    -2.24 (-10.73%)
     
  • GBP/USD

    1.3723
    +0.0002 (+0.02%)
     
  • USD/JPY

    110.3410
    +0.0400 (+0.04%)
     
  • BTC-USD

    44,508.07
    +885.64 (+2.03%)
     
  • CMC Crypto 200

    1,113.32
    +4.39 (+0.40%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    30,198.35
    +558.95 (+1.89%)
     

Adicet Bio to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January.

Details of the events are as follows:

H.C. Wainwright Bioconnect 2021 Conference
The presentation will be available for on-demand viewing starting January 11, 2021 at 6:00 AM ET.

B. Riley Securities' Oncology Investor Conference
Fireside chat on January 20, 2021 at 3:30 PM ET.

A replay of the pre-recorded H.C. Wainwright presentation can be accessed on January 11, 2021 in the investors section of the Company’s website, and a live webcast of the B. Riley presentation can be accessed in the same section of the Company’s website.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com